CVR 44607379Private limited company (ApS)Fremstilling af farmaceutiske præparater (212000)Stensmosevej 24, 2620 AlbertslundFounded 1 Feb 2024
Compare withsimilar companiesanother companyits industry
Alpine-Bio ApS
The newest trades with a company on a side are on the latest property trades.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Alpine-Bio ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
1
CVR, Mar 2026
0 (0%) over 12 months
Result
-61.7K
DKK, annual report 2025
Equity
621.6K
DKK, annual report 2025
JUUZ ApSCVR 30815645, 66.7% to under 90% of capital and votes
S21 Holding ApSCVR 43647180, 20% to under 25% of capital and votes
Group holding company
Dandex estimate: investments in group enterprises in the 2025 report, controlled by a companySøren Anker Nielsensince 1 Feb 2024
Owners of 5% or more. CVR registers shares in bands, not exact figures.
CVR 3081564566.7% to under 90% of capital and votesnotified 14 Apr 2025since 1 Feb 2024
CVR 4364718020% to under 25% of capital and votesnotified 2 Dec 2025since 28 Feb 2024
10% to under 15% of capital and votes28 Feb 2024 to 28 Feb 2024
Ultimate controller
Holding in JUUZ ApS, since 4 Sep 2007
Holding company
CVR 30815645Private limited company (ApS)
Holding in Alpine-Bio ApS, since 1 Feb 2024
This company
Alpine-Bio ApS
CVR 44607379
1 Danish company.
SubsidiaryCVR 27210341100% of capital and votes
Danish companies held at 5% or more, from the CVR owner register (ejerregister), and their holdings one level down. Foreign holdings are not in CVR. Subsidiary (datterselskab): 50% or more of the votes, a Dandex estimate; in the 50% band a joint venture is not ruled out.
CVR 5605282833.3% to under 50% of capital and votes28 Feb 2024 to 3 Feb 2026
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Mar 2026, monthly: 1 employee, 0 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Mar 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| FTE | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest Mar 2026, published 21 May 2026.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2025, DKK: Operating profit -56.7K, Result for the year -61.7K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 3.3M, Equity 621.6K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2024 | 2025 |
|---|---|---|
| Operating profit | -157 | -57 |
| Result for the year | -157 | -62 |
| Equity | 383 | 622 |
| Total assets | 1,990 | 3,293 |
| Employees (average) | 1 | 1 |
Not every period is a full year: 2024 covers 11 months (1 Feb to 31 Dec 2024). Changes against it compare periods of different length.
Annual report 2025
Published 24 Apr 2026
Annual report 2024
1 Feb 2024 to 31 Dec 2024, published 19 Jun 2025
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseDebt conversionPaid in 550,000 | None | 550,000 | None | 46,889 | |
| IncreaseDebt conversionPaid in 500,000 | None | 500,000 | None | 44,444 | |
| FoundingCashPaid in 40,000 | None | 40,000 | None | 40,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The company's own figures, in DKK, from the annual reports filed in XBRL.
| DKK thousands | 2024 | 2025 |
|---|---|---|
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | |
| Employee growth (vækst i antal ansatte) | Not reportednote 1 | 0% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | |
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | |
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | |
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | |
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | |
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | |
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions.
How each credit metric is calculated:
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Source: CVR, read 21 Nov 2026.
5 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Ny adresse: Stensmosevej 24A, 2620 Albertslund
Ny kommune: Albertslund
Vedtægter ændret: 14.04.2025
Kapitalforhøjelsen er besluttet den 14.04.2025.
kr. 1.111,11, indbetalt ved konvertering af gæld, kurs 22.500,02. kr. 1.333,33, indbetalt ved konvertering af gæld, kurs 22.500,05.
Kapitalen udgør herefter kr. 46.888,88.
Vedtægter ændret: 26.06.2024
Nye binavne: AlpineBio ApS, BIOAI ApS
Vedtægter ændret: 28.02.2024
Nyt binavn: Alpine-Labs ApS
Kapitalforhøjelsen er besluttet den 28.02.2024.
kr. 4.444,44, indbetalt ved konvertering af gæld, kurs 11.250,02.
Kapitalen udgør herefter kr. 44.444,44.
Stiftelsesdato: 01.02.2024.
Virkningsdato: 01.02.2024.
Seneste vedtægtsdato: 01.02.2024.
Kapital:
kr. 40.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 40.000,00 til kurs 100,00, fuldt indbetalt.
Stifter:
CVR-NR. 30815645 JUUZ ApS, Gammel Strandvej 410, 3060 Espergærde, den 01.02.2024.
Direktion:
Søren Anker Nielsen, den 01.02.2024.
Selskabet tegnes af en direktør
Første regnskabsår:
01.02.2024 - 31.12.2024.
Regnskabsår:
01.01 - 31.12.
Formål:
Selskabets formål er at drive virksomhed med at udvikle, licensiere, udlicensiere, fremstille,sælge lægemidler, medicinsk udstyr, samt med køb og salg af aktier og anparter, og enhvervirksomhed i hermed stående forbindelse.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 21 Nov 2026.
What Pro holds for Alpine-Bio ApS:
Have Pro? Sign in.
P-number 1030060659Stensmosevej 24, 2620 Albertslund